This inventor holds 22 USPTO granted patents, primarily in Quinoline Derivatives. Top assignees: Eli Lilly and Company, Dowelanco, Other. Active years: 1976-1995.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Indianapolis, IN (US) (1976 - 1983)
- Oxfordshire, GB (1993)
- Marcham, Oxfordshire, GB (1994)
- Lawrence, IN (US) (1983 - 1995)
Company Filing History:
15 out of 4,514 
6 out of 137 
1 out of 834,513 Years Active: 1976-1995
Areas of Expertise:
Title: The Innovative Journey of Inventor Barry A. Dreikorn
Introduction: Barry A. Dreikorn, an accomplished inventor based in Indianapolis, Indiana, has made significant contributions to the field of pharmaceutical chemistry. With a remarkable portfolio of 22 patents, Dreikorn's work focuses primarily on quinazoline derivatives, which have valuable applications in medicinal chemistry.
Latest Patents: Among his latest innovations, Dreikorn has developed a class of substituted quinazolines, represented by complex chemical structures. These compounds exhibit a variety of substituents, including hydrogen, halo groups, and alkyl chains, which can enhance their therapeutic potential. His work also includes the synthesis of 4-(2-(4-(2-pyridinyloxy)phenyl)ethoxy)quinazoline and its analogues. These compounds feature heterocycles such as pyridyl, pyrazinyl, and pyrimidinyl, all of which are designed to optimize efficacy in medicinal applications.
Career Highlights: Barry's impressive career includes pivotal roles at prominent companies such as Eli Lilly and Company and Dowelanco. His experiences in these reputable organizations have honed his expertise in drug development and innovation, significantly contributing to his extensive patent portfolio.
Collaborations: Throughout his career, Barry A. Dreikorn has collaborated with esteemed colleagues, including Robert G. Suhr and Glen P. Jourdan. Their combined efforts have resulted in groundbreaking research and advancements in the field of medicinal chemistry, showcasing the importance of teamwork in achieving innovative results.
Conclusion: Barry A. Dreikorn stands as a notable figure in the realm of inventions, with a strong focus on the development of quinazoline derivatives. His 22 patents reflect his dedication to enhancing pharmaceutical science, and his collaborations with industry professionals further emphasize his impact on innovations in the field. As he continues his work, Dreikorn is sure to inspire future generations of inventors and researchers alike.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile